Journal article
Marginal Zone Lymphoma: Clinicopathologic Variations and Approaches to Therapy
Current oncology reports, Vol.20(4), pp.33-11
04/01/2018
DOI: 10.1007/s11912-018-0687-9
PMID: 29572581
Abstract
Purpose of Review The purpose of the study is to summarize the current conundrums in the management of marginal zone lymphomas (MZL).
Recent Findings In 2017, the US Food and Drug Administration (FDA) approved ibrutinib, a first in class Bruton Tyrosine Kinase inhibitor, for the treatment of relapsed/refractory MZL based on pivotal open-label phase II trial demonstrating an overall response rates of 48%. Clinical trials design utilizing chemotherapy-free regimens for relapsed/refractory disease are gaining popularity. Recent studies have identified multiple genetic biomarkers that helped characterize and prognosticate different subtypes of MZL.
Summary MZLs are heterogeneous, mostly indolent, malignancies derived from B lymphocytes. Three disease subtypes are recognized, extranodal, nodal, and splenic. The disease characteristics, clinical picture, and treatment algorithms vary considerably based on subtype and site of involvement. Recent discoveries have enhanced our knowledge of the pathogenesis of MZLs leading to development of more accurate prognostic models as well as novel targeted systemic therapies.
Details
- Title: Subtitle
- Marginal Zone Lymphoma: Clinicopathologic Variations and Approaches to Therapy
- Creators
- Sabarish Ayyappan - The Ohio State UniversityBasem M. William - The Ohio State University
- Resource Type
- Journal article
- Publication Details
- Current oncology reports, Vol.20(4), pp.33-11
- Publisher
- Springer Nature
- DOI
- 10.1007/s11912-018-0687-9
- PMID
- 29572581
- ISSN
- 1523-3790
- eISSN
- 1534-6269
- Number of pages
- 11
- Language
- English
- Date published
- 04/01/2018
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984359664302771
Metrics
11 Record Views